ClinicalTrials.gov
ClinicalTrials.gov Menu

The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03479437
Recruitment Status : Recruiting
First Posted : March 27, 2018
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
Rhythm Pharmaceuticals, Inc.

Brief Summary:
A voluntary prospective study that will allow registration and follow-up of individuals with MC4R pathway genetic obesity.

Condition or disease
Genetic Forms of Extreme Obesity

Detailed Description:

Potential patients will be referred to coordinating centers by their healthcare provider (treating physician, diagnosing physician or primary care physician) and if eligible will be invited to enroll in the registry. The Registry Coordinating Center will be responsible for obtaining consent from adult patients and caregivers of minor patients (as well as assent from minors when appropriate), screening patients and enrolling them in the registry.

The registry will capture data entered by the patient, the patient's healthcare provider, and the patient's caregiver using online (electronic) survey tools administered at baseline, and annually thereafter. The patient's healthcare provider will complete the baseline Healthcare Provider survey tool, reporting the patient's baseline demographics, medical history, clinical information, and disease characteristics. The patient and caregiver will complete their dedicated baseline survey tools answering questions on the impact of disease on their everyday life. Survey tools include questions on patient and caregiver demographics, patient physical activity, patient food and hunger episodes, patient quality of life, and caregiver's perspective of disease burden on the family. Registry patients, caregivers, and healthcare providers will be contacted annually (approximately every 12 months) by the Registry Coordinating Center to complete an online follow-up survey tool including a smaller subset of questions from the baseline survey tools.


Study Type : Observational [Patient Registry]
Estimated Enrollment : 1000 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Involving Variants in Hypothalamic Genes Upstream or Downstream From the Melanocortin-4 Receptor (MC4R)
Actual Study Start Date : April 15, 2018
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Gelusil




Primary Outcome Measures :
  1. Assessment of Quality of Life [ Time Frame: 5 years ]
    Evaluate the quality of life through annual patient and caregiver reported surveys.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Extreme obesity in adults age 18 or older defined as a BMI >40 kg/m2 or subjects from age 2 through age 18 years with a BMI value that is >1.4 times the corresponding age/gender 95th percentile value will be eligible.

Second, specific genotypic criteria involving defined major genes contributing to genetic obesity disorders will also be required for enrollment.

Patients will be eligible to participate in the registry regardless of gender or geographic location. Other genetic forms of obesity may be added to this list as pathogenetic etiologies and the potential involvement of specific genes in the hypothalamus upstream or downstream of the MC4R become better understood.

All known patients, or their caregivers, will be invited to participate. As new patients resulting from novel gene variants or defects are identified, registry patient enrollment will continue on an ongoing basis.

Criteria

Inclusion Criteria:

  1. Extreme obesity patients aged 2 years and older.
  2. Extreme obesity defined as:

    1. BMI > 40 kg/m2 in patients 18 years of age or older.
    2. BMI value that is >1.4 times the corresponding age/gender 95th percentile value in patients who are 2 through 17 years of age.
  3. At least one of the following genotypes:

    1. Bi-allelic (homozygous or compound heterozygous) POMC, PCSK1, LEPR variants leading to the physician-confirmed diagnosis of either POMC or LEPR deficiency obesity.
    2. The presence of high-confidence, high-impact genetic variations (homozygote, compound heterozygote, heterozygote or composite heterozygote [i.e., heterozygous variants in more than a single gene]) in these same 3 genes (POMC, PCSK1 and LEPR) associated with the clinical presentation of extreme obesity
    3. The presence of other high-confidence, high-impact genetic variations (homozygote, compound heterozygote, heterozygote or composite heterozygote in the MC4R gene or other upstream MC4R-pathway genes and selected variants downstream in the MC4R-pathway (Table 1) that are carried by extreme obesity patients who do not demonstrate specific syndromic obesity clinical presentations. Selected Bardet-Biedl syndrome (BBS1 through BBS21) genetic variants or Alström syndrome (ALMS) genetic variants possibly contributing to non-syndromic forms of clinical extreme obesity will be eligible for enrollment.
  4. Study participant and/or parent or caregiver can understand and comply with the requirements of the study, and able to understand and sign the written informed consent (IC)/assent, after being informed about the study.

Exclusion Criteria:

  1. Patients with syndromic forms of obesity such as Bardet-Biedl syndrome or Alström syndrome. These patients will be referred to existing registries for these specific syndromic obesity (e.g., Clinical Registry in Bardet-Biedl syndrome [CRIBBS] for BBS patients).
  2. Individual is, in the opinion of the study investigator, not suitable to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03479437


Contacts
Contact: Amy McCagg 8572544271 amccagg@rhythmtx.com

Locations
United States, Ohio
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
Contact: Jinyu (Jenny) Xu    614-722-3598    ResearchCHWN@nationwidechildrens.org   
Sponsors and Collaborators
Rhythm Pharmaceuticals, Inc.
Investigators
Principal Investigator: Ihuoma Eneli Nationwide Children's Hospital
Study Chair: Liz Stoner Rhythm Pharmaceuticals, Inc.

Responsible Party: Rhythm Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03479437     History of Changes
Other Study ID Numbers: RM-493-020
First Posted: March 27, 2018    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Rhythm Pharmaceuticals, Inc.:
Obesity
Melanocortin
TEMPO
MC4R
Genetic Obesity
hypothalamic
POMC
LEPR
PCSK1

Additional relevant MeSH terms:
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
TEMPO
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs